QIAN Zhiling , CUI Shichang , WANG Haiyan.
  • Department of Liver 5, Beijing You’an Hospital, Capital Medical University, Beijing 100069, ChinaCorresponding Author: QIAN Zhi-ling, E-mail: jingguangzhang@sina.com;
Primary hepatocellular carcinoma; Embolization treatment; Radiofrequency ablation
Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables References Cited by

Objective　 To evaluate the efficacy of transcatheter arterial chemoembolization (TACE) combined with radiofrequency ablation (RFA) in treating primary hepatocellular carcinoma (HCC).
Methods 　From March 2004 to March 2006, 137 patients with primary HCC underwent TACE alone (n=87) and TACE+RFA (n=50), respectively, after the interventional treatment, all patients periodically received CT reexaminations and alpha fetoprotein (AFP) measurement. The therapeutic efficacy, AFP level and survival rate between two groups were compared with each other.
Results 　In TACE group the effective rate (CR+PR) was 34.5%, AFP decreasing amplitude was 54.2%, and 2 years survival rate was 43.7%. While in TACE+RFA group, the effective rate (CR+PR) was 70.0%, AFP decreasing amplitude was 78.0%, and 2 years survival rate was 62.0%, there were significant differences between two groups (P＜0.05).
Conclusion 　Combined application of TACE and RFA is significantly superior to TACE alone in treatment of primary HCC.

Citation： QIAN Zhiling,CUI Shichang,WANG Haiyan.. Clinical Study on Efficacy of Transcatheter Arterial Chemoembolization Combined with Radiofrequency Ablation in Treating Hepatocellular Carcinoma. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2008, 15(9): 686-689. doi: Copy